Status:
TERMINATED
Effect of TF-TAVR on Emotional Status, Quality of Life, Frailty and Inflammation
Lead Sponsor:
Medical University of Graz
Conditions:
Aortic Valve Stenosis
Clinical Trial
Eligibility:
All Genders
18+ years
Brief Summary
Aortic valve stenosis (AS) shows high and increasing prevalence in Western civilizations and leads to high morbidity and mortality. 15 years ago Alain Cribier performed the first catheter-based transf...
Detailed Description
Aortic valve stenosis (AS) shows a high prevalence in Western civilizations with an increasing incidence and is associated with high morbidity and mortality. AS is a degenerative disease and therefore...
Eligibility Criteria
Inclusion
- Symptomatic aortic valve stenosis
- Planned elective transcatheter aortic valve replacement
- Willingness and ability to provide signed informed consent (IC) form prior to participation in any study-related procedures
Exclusion
- Disease reducing life expectancy to \< 1 year
- Severe immune-system modulating or -affecting disease
Key Trial Info
Start Date :
November 6 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT03308435
Start Date
November 6 2017
End Date
December 31 2020
Last Update
January 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Graz
Graz, Austria, 8010